Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Dana Farber Cancer Institute
Boston, Massachusetts, United States
Robert Schlossman, MDRecruiting - Tufts Medical Center
Boston, Massachusetts, United States
Withdrawn - University of North Carolina at Chapel Hill
Chapel Hill, North Carolina, United States
Peter Voorhees, MDRecruiting - Duke University Medical Center
Durham, North Carolina, United States
Cristina Gasparetto, MDRecruiting - University of Cincinnati
Cincinnati, Ohio, United States
John Morris, MDRecruiting - Sarah Cannon Research Institute
Nashville, Tennessee, United States
Jesus G. Berdeja, MDRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Mar 2012
- Primary completion
- 31 Mar 2014
- Completion
- 30 Sept 2014
- Last update posted
- 4 Jun 2013
- Registered enrollment
- 40
- Registry id
- NCT01695590
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.